Bispecific PD-1 and TIGIT binding proteins and uses thereof

Patent metadata

Field	Value
Publication number	US-12570744-B2
Application number	US-202418441469-A
Country	US
Kind code	B2
Filing date	Feb 14, 2024
Priority date	Apr 30, 2021
Publication date	Mar 10, 2026
Grant date	Mar 10, 2026

Abstract

The disclosure relates to binding proteins, including antibodies, that bind to Programmed Death-1 (“PD-1”) and T cell immunoreceptor with Ig and ITIM domains (“TIGIT”). The disclosure also provides compositions comprising such binding proteins and nucleic acid molecules encoding such binding proteins. The disclosure further relates to methods of treating a disorder or condition using such binding proteins.

First claim

What is claimed is:

1 . A bispecific binding protein that specifically binds to PD-1 and TIGIT comprising:
a) a first binding domain that specifically binds to PD-1, wherein the first binding domain comprises a heavy chain variable domain comprising a HCDR1 comprising the amino acid sequence of SEQ ID NO: 1, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 2, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 3, and a light chain variable domain comprising a LCDR1 comprising the amino acid sequence of SEQ ID NO: 4, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 5 and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 6; and b) a second binding domain that specifically binds to TIGIT, wherein the second binding domain comprises a heavy chain variable domain comprising a HCDR1 comprising the amino acid sequence of SEQ ID NO: 11, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 12, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 13, and a light chain variable domain comprising a LCDR1 comprising the amino acid sequence of SEQ ID NO: 14, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 15, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; wherein first binding domain that specifically binds to PD-1 comprises a heavy chain variable domain comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 7 and a light chain variable domain comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 9; and wherein the second binding domain that specifically binds to TIGIT comprises a heavy chain variable domain comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 17 and a light chain variable domain comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 19.

2 . The bispecific binding protein of claim 1 , wherein first binding domain that specifically binds to PD-1 comprises a heavy chain comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 8 and a light chain comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 10.

3 . The bispecific binding protein of claim 2 , wherein the second binding domain that specifically binds to TIGIT comprises a heavy chain comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 18 and a light chain comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 20.

4 . The bispecific binding protein of claim 1 , wherein the bispecific binding protein is an IgG1 antibody and comprises a L234F/L235E/P331S triple mutation (TM).

5 . The bispecific binding protein of claim 1 , wherein the equilibrium dissociation constant (K D ) of the bispecific binding protein—human TIGIT interaction is from about 9 pM to about 15 pM.

6 . The bispecific binding protein of claim 5 , wherein the equilibrium dissociation constant (K D ) of the bispecific binding protein—human PD-L1 interaction is from about 0.3 nM to about 0.5 nM.

7 . The bispecific binding protein of claim 1 , comprising a variant Fc region wherein the variant Fc region comprises at least one substitution selected from 221K, 221Y, 225E, 225K, 225W, 228P, 234D, 234E, 234N, 234Q, 234T, 234H, 234Y, 234I, 234V, 234F, 235A, 235D, 235R, 235W, 235P, 235S, 235N, 235Q, 235T, 235H, 235Y, 235I, 235V, 235E, 235F, 236E, 237L, 237M, 237P, 239D, 239E, 239N, 239Q, 239F, 239T, 239H, 239Y, 240I, 240A, 240T, 240M, 241W, 241L, 241Y, 241E, 241R, 243W, 243L 243Y, 243R, 243Q, 244H, 245A, 247L, 247V, 247G, 250E, 250Q, 251F, 252L, 252Y, 254S, 254T, 255L, 256E, 256F, 256M, 257C, 257M, 257N, 262I, 262A, 262T, 262E, 263I, 263A, 263T, 263M, 264L, 264I, 264W, 264T, 264R, 264F, 264M, 264Y, 264E, 265A, 265G, 265N, 265Q, 265Y, 265F, 265V, 265I, 265L, 265H, 265T, 266I, 266A, 266T, 266M, 267Q, 267L, 268E, 269H, 269Y, 269F, 269R, 270E, 280A, 284M, 292P, 292L, 296E, 296Q, 296D, 296N, 296S, 296T, 296L, 296I, 296H, 296G, 297S, 297D, 297E, 298A, 298H, 298I, 298T, 298F, 299I, 299L, 299A, 299S, 299V, 299H, 299F, 299E, 305I, 308F, 313F, 316D, 318A, 318S, 320A, 320S, 322A, 322S, 325Q, 325L, 325I, 325D, 325E, 325A, 325T, 325V, 325H, 326A, 326D, 326E, 326G, 326M, 326V, 327G, 327W, 327N, 327L, 328S, 328M, 328D, 328E, 328N, 328Q, 328F, 328I, 328V, 328T, 328H, 328A, 329F, 329H, 329Q, 330K, 330G, 330T, 330C, 330L, 330Y, 330V, 330I, 330F, 330R, 330H, 331G, 331A, 331L, 331M, 331F, 331W, 331K, 331Q, 331E, 331S, 331V, 331I, 331C, 331Y, 331H, 331R, 331N, 331D, 331T, 332D, 332S, 332W, 332F, 332E, 332N, 332Q, 332T, 332H, 332Y, 332A, 333A, 333D, 333G, 333Q, 333S, 333V, 334A, 334E, 334H, 334L, 334M, 334Q, 334V, 334Y, 339T, 370E, 370N, 378D, 392T, 396L, 416G, 419H, 421K, 428L, 428F, 433K, 433L, 434A, 434W, 434Y, 436H, 440Y and 443W as numbered by the EU index as set forth in Kabat.

8 . The bispecific binding protein of claim 7 , wherein the variant Fc region comprises a M252Y/S254T/T256E (YTE) mutation.

9 . The bispecific binding protein of claim 7 , wherein the Fc variant region comprises a L234F/L235E/P331S triple mutation (TM).

10 . The bispecific binding protein of claim 1 , comprising an Fc region, wherein the Fc region has reduced fucosylation or is afucosylated.

11 . A pharmaceutical composition comprising bispecific binding protein of claim 1 , and a pharmaceutically acceptable carrier.

12 . The pharmaceutical composition of claim 11 , further comprising an anti-cancer compound selected from pemetrexed, carboplatin, gemcitabine, cisplatin, paclitaxel or combinations thereof.

13 . A nucleic acid comprising a nucleotide sequence encoding the bispecific binding protein of claim 1 .

14 . A vector comprising the nucleic acid of claim 13 .

15 . A host cell comprising the vector of claim 14 .

16 . A method of treating cancer in a subject, the method comprising administering to the subject a therapeutically effective amount of the nucleic acid of claim 13 .

17 . A method of treating cancer in a subject, the method comprising administering to the subject the bispecific binding protein of claim 1 .

18 . The method of claim 17 , wherein the cancer is one or more of ovarian cancer, breast cancer, colorectal cancer, prostate cancer, cervical cancer, uterine cancer, testicular cancer, bladder cancer, head and neck cancer, melanoma, pancreatic cancer, renal cell carcinoma, lung cancer, or non-small cell lung cancer (NSCLC).

19 . A method of treating cancer in a subject, the method comprising administering to the subject a therapeutically effective amount of the bispecific binding protein of claim 1 in combination with an anti-cancer compound selected from pemetrexed, carboplatin, gemcitabine, cisplatin, paclitaxel or combinations thereof.

20 . A method of treating cancer in a subject, the method comprising administering the nucleic acid of claim 13 in combination with an anti-cancer compound selected from pemetrexed, carboplatin, gemcitabine, cisplatin, paclitaxel or combinations thereof.

Assignees

• Medimmune Llc

Inventors

• Mazor Yariv
• Wang Yue
• Moody Gordon
• Malhotra Deepali
• Overstreet Michael
• Clancy-Thompson Eleanor
• Lee Karin
• Pryts Stacy
• Hammond Scott

Classifications

• C07K2317/92

  Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title

• C07K2317/72

  Increased effector function due to an Fc-modification · CPC title

• C07K2317/565

  Complementarity determining region [CDR] · CPC title

• C07K2317/31

  multispecific · CPC title